Stay updated with breaking news from Travis Whitfill. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
ATR-04 is in development for epidermal growth factor receptor inhibitor -induced dermal toxicity, which affects approximately 150,000 patients in the US Reduces methicillin-resistant S. aureus by...
Azitra will present two oral presentations at ASGCT Baltimore, MD, May 7-11, 2024 related to ATR-12, Azitra’s candidate for Netherton syndrome Topical application of ATR-12 to ex vivo human...
Newly granted patent protects a filaggrin-secreting strain of Staphylococcus epidermidis for the treatment of ichthyosis vulgaris Ichthyosis vulgaris is a high unmet need with no FDA-approved...
Azitra, Inc. , a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that the U.S. Patent and Trademark Office (USPTO) has issued U.S. patent No. 11,850,267 covering future...
Azitra, Inc. , a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that management will present at the Dermatology Summit...